Fiscal Year:	FY 2024	**Task Last Updated:**	FY 07/12/2023
PI Name:	Zwart, Sara Ph.D.		
Project Title:	B Complex: 5-Methyltetrahydrofolate, Riboflavin, Pyridoxine, and Methylcobalamin Supplementation as a Non-Mechanical Countermeasure to Mitigate Optic Disc Edema Changes During Strict 6° Head-Down Tilt Bed Rest		
Division Name:	Human Research		
Program/Discipline:			
Program/Discipline--Element/Subdiscipline:			
Joint Agency Name:		**TechPort:**	No
Human Research Program Elements:	(1) **HHC**:Human Health Countermeasures		
Human Research Program Risks:	(1) **SANS**:Risk of Spaceflight Associated Neuro-ocular Syndrome (SANS)		
Space Biology Element:	None		
Space Biology Cross-Element Discipline:	None		
Space Biology Special Category:	None		
PI Email:	sara.zwart-1@nasa.gov	**Fax:**	FY
PI Organization Type:	NASA CENTER	**Phone:**	281-483-3753
Organization Name:	NASA Johnson Space Center		
PI Address 1:	Department of Preventive Medicine and Community Health		
PI Address 2:	2101 Nasa Pkwy, Mail Stop SK3		
PI Web Page:			
City:	Houston	**State:**	TX
Zip Code:	77058-3607	**Congressional District:**	36
Comments:			
Project Type:	GROUND	**Solicitation / Funding Source:**	2018-2019 HERO 80JSC018N0001-SANS: Spaceflight Associated Neuro-ocular Syndrome Countermeasures. Appendix C
Start Date:	10/01/2019	**End Date:**	09/30/2024
No. of Post Docs:	0	**No. of PhD Degrees:**	0
No. of PhD Candidates:	0	**No. of Master' Degrees:**	0
No. of Master's Candidates:	0	**No. of Bachelor's Degrees:**	0
No. of Bachelor's Candidates:	0	**Monitoring Center:**	NASA JSC
Contact Monitor:	Stenger, Michael	**Contact Phone:**	281-483-1311
Contact Email:	michael.b.stenger@nasa.gov		
Flight Program:			
Flight Assignment:	End date changed to 09/30/2024 per C. Ribeiro/HHC (Ed., 10/2/2023).		
Key Personnel Changes/Previous PI:	No changes		
COI Name (Institution):	Chen, John M.D., Ph.D. (Mayo Clinic Rochester) Egert, Sarah Ph.D. (University of Hohenheim, Germany) Heer, Martina Ph.D. (Rheinische Friedrich-Wilhelms-Universitat Bonn, Germany) Laurie, Steven Ph.D. (KBR/NASA Johnson Space Center) Macias, Brandon Ph.D. (NASA Johnson Space Center) Smith, Scott Ph.D. (NASA Johnson Space Center)		
Grant/Contract No.:	Internal Project		
Performance Goal No.:			
Performance Goal Text:			

Task Description:	NOTE: Per the Principal Investigator (PI), the study has been reduced to 4 campaigns (from 6 originally planned), and a proposed countermeasure – a B-vitamin supplement – was deselected from the study (Ed.,10/20/22). Approximately 20% of astronauts on International Space Station (ISS) missions have experienced ophthalmic pathologies including optic disc edema, one aspect of what is characterized as Spaceflight Associated Neuro-ocular Syndrome, or SANS. While the precise cause for SANS is not known, it is likely that there are multiple contributing factors, including genetic and environmental factors that may affect the response to headward fluid shifts. B-vitamin status, one carbon biochemistry, and the presence of specific one-carbon metabolic pathway single nucleotide polymorphism (SNP) alleles were significant predictors for the incidence of astronaut ophthalmic pathologies, including optic disc edema, choroidal folds, and cotton wool spots. When looking at the individual SNPs, the G allele of methionine synthase reductase (MTRR, rs1801394) A66G and the C allele of serine hydroxymethyltransferase-1 (SHMT1, rs1979227) C1420T were associated with higher incidence of spaceflight-induced ophthalmic changes compared to those with the A or T alleles. In ground-analog studies, end-tidal CO2, a reflection of arterial CO2, response to acute head-down tilt (HDT) and CO2 exposure was also related to G and C alleles of MTRR A66G and SHMT1 C1420T and B-vitamin status. Likewise, in a recent bed rest study where subjects were exposed to strict 6°-HDT bed rest and 0.5% CO2 for 30 days, 5 out of 11 subjects developed optic disc edema. The number of SHMT1 C1420T C and MTRR A66G G alleles were significantly associated with the change in total retina thickness, a quantitative measure of optic disc edema. There are several possibilities to explain how one-carbon metabolism could lead to the ocular phenotypes in some individuals after spaceflight or bed rest. One-carbon metabolism is intimately involved in maintaining endothelial function through maintenance of endothelial nitric oxide (NO) synthase and NO production. We have proposed a multi-hit hypothesis, with genetics and B vitamin status, along with potential factors or “multiple hits” contributing to endothelial dysfunction (e.g., CO2 exposure, fluid shifts, altered endocrine function, radiation exposure). The resulting endothelial dysfunction could lead to cerebral microvascular edema, which can impede cerebrospinal fluid outflow and impinge on the optic nerve and eye. Furthermore, decreased NO and increased peroxynitrite can also affect collagen and elastin integrity through activation of matrix metalloproteinases (MMPs). Specifically, MMP activation can affect collagen and elastin cross-linking, firmness, and elasticity, particularly in the sclera and lamina cribrosa, which are collagen-containing layers of the eye. Differences in elasticity of the sclera and lamina cribrosa could affect an individual’s response to a headward fluid shift during bed rest or spaceflight. Dietary B-vitamin insufficiencies and variants in genes involved in the one-carbon metabolic pathway can contribute to pathway inefficiency, which can affect numerous outcomes, including NO production and endothelial function. This would also explain why after exposure to microgravity, fluid shift, CO2, and/or other factors – only a subset of individuals develop optic disc edema. We hypothesize here that supplementing with required cofactors (i.e., B-vitamins) can increase one-carbon pathway efficiency and ultimately prevent or mitigate spaceflight- and bed rest-induced optic disc edema.
Rationale for HRP Directed Research:	
Research Impact/Earth Benefits:	The implications of this research for one of NASA’s highest priority crew health risks are significant, along with the implications for a better understanding of the role of one-carbon metabolism in the health of the general population.
Task Progress:	After receiving Authority to Proceed on August 30, 2019, the Institutional Revew Board (IRB) documentation was developed and submitted for review. IRB approval was obtained in May 2020 and a renewal was approved in April 2021. The SANS Countermeasures study has been reduced to 4 campaigns (from 6 originally planned), and our proposed countermeasure – a B-vitamin supplement – was deselected from study. [Ed. Note: SANS is the acronym for Spaceflight Associated Neuro-ocular Syndrome.] This was due to the regulatory burden at the German Aerospace Center (Deutsches Zentrum für Luft- und Raumfahrt / DLR) that would be required to support this B-Complex study. The study would have been classified as a Clinical Trial, and DLR was not poised to support such a study. Despite the fact that the B-Complex supplement will not be tested in this study, all of the genetics and biochemistry analyses from our proposed study are still planned for the 4 campaigns and will provide valuable information. The current timeline for the 4 campaigns is: • Campaign 1 and 2: lower body negative pressure (LBNP) and 6-hour seated (12 subjects per campaign) -- Campaign 1 baseline data collection (BDC) started on 9/28/21 and ended 12/1/21 -- Campaign 2 BDC started 1/24/22 and ended 3/29/22 • Campaign 3 and 4: exercise countermeasure (CM) and strict head-down tilt (HDT) (12 subjects per campaign) -- Campaign 3 started 1/23/23 and ended 3/28/23 -- Campaign 4 started 5/1/23 and ended 7/4/23 Blood samples from Campaigns 1-3 have been received. Blood samples from Campaign 4 are scheduled to be shipped in July 2023. Once samples are received, analyses will begin.
Bibliography Type:	Description: (Last Updated:)